|
Dec 10, 2024
|
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome
|
|
|
Nov 14, 2024
|
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
|
|
|
Nov 13, 2024
|
AC Immune to Present at the Jefferies 2024 London Healthcare Conference
|
|
|
Nov 05, 2024
|
AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
|
|
|
Sep 17, 2024
|
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease
|
|
|
Aug 28, 2024
|
AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions
|
|
|
Aug 06, 2024
|
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
|
|
|
Jul 31, 2024
|
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024
|
|
|
Jul 25, 2024
|
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease
|
|
|
Jul 16, 2024
|
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
|
|